ArticleDiabetes/metabolism research and reviews2026
Metabolomic Profiling Delineates Stage-Associated Metabolic Remodelling in Cardiovascular-Kidney-Metabolic Syndrome.
Article in Diabetes/metabolism research and reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsCardiovascular-kidney-metabolic (CKM) syndrome represents an integrated continuum of metabolic, kidney, and cardiovascular abnormalities. However, the stage-specific metabolic heterogeneity underlying this clinical framework remains incompletely characterised. MATERIALS AND
methodsWe performed plasma metabolomic profiling in 1374 participants from the China Multi-Ethnic Cohort across CKM stages 0-4. Participants from Chengdu and Chongqing provinces comprised the discovery cohort (n = 969), whereas those from Yunnan province comprised the validation cohort (n = 405). Stage-associated metabolites were identified using prespecified pairwise comparisons with OPLS-DA and covariate-adjusted limma analyses. Weighted correlation network analysis identified coordinated metabolic modules. Machine-learning models were developed to evaluate discrimination of advanced CKM (stages 3-4) using metabolite signatures independent of conventional CKM-defining variables.
resultsAmong 858 endogenous metabolites, 261 unique metabolites were associated with CKM stages, revealing distinct metabolic patterns from early to advanced CKM. Stage 1 was characterised by altered lipid- and bile acid-related metabolites, stage 2 by broader lipid and amino-acid remodelling, and stage 3 by additional carbohydrate, aromatic amino-acid, secondary bile acid, host-microbial, and renal-handling signals. Metabolic separation between stages 3 and 4 was comparatively weak. WGCNA identified a CKM-associated turquoise module, with γ-glutamylvaline as a hub metabolite. A model incorporating age, sex, and eight metabolites derived from the discovery cohort showed favourable performance for distinguishing advanced CKM from earlier stages and achieved an AUROC of 0.874 (95% CI, 0.802-0.931) in the validation cohort.
conclusionsCKM stages exhibit distinct and non-linear metabolic signatures. A compact metabolomic panel independent of conventional CKM-defining variables may provide complementary molecular information for advanced CKM phenotyping and future risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.